The All Ordinaries Index (ASX: XAO) is down 0.2% today, despite the best efforts of this rocketing ASX All Ords stock.
The surging company in question is 4DMedical Ltd (ASX: 4DX).
Shares in the respiratory imaging technology company closed Friday trading for $1.545. In morning trade on Monday, shares are swapping hands for $1.990 apiece, up 28.8%.
As you may know, 4DMedical shares have been among the top-performing ASX All Ords stocks over the past year. The company's shares are now up 373.8% in 12 months amid a string of successes with its lung analysis products.
Here's what's grabbing ASX investor interest again today.
Image source: Getty Images
ASX All Ords stock surges on three new agreements
The 4DMedical share price is charging higher after the company reported inking agreements with a leading global pharmaceutical company, Royal Melbourne Hospital, and Spectrum Medical Imaging to deploy its lung health analysis software.
The agreements run to 2027 and are intended to support lung cancer screening and improve lung health assessment. The company said this includes the recently commenced National Lung Cancer Screening Program (NLCSP) in Australia.
4DMedical reported that it has commenced the rollout of Lung Health Screening in Brazil. The initial agreement covers the analysis of up to 10,000 scans through to August 2026.
And Royal Melbourne Hospital has entered into a pilot agreement with the ASX All Ords stock to deploy the full 4DMedical portfolio to support advanced lung ventilation analysis and clinical imaging assessment of lung health.
As for the third agreement, Spectrum Medical Imaging inked a deal to support its Lung Health programs. The agreement commences immediately and will run until 30 June 2027.
What did management say?
Commenting on the new agreements sending the ASX All Ords stock soaring today, 4DMedical CEO and founder Andreas Fouras said, "In parallel to our US efforts to bring CT:VQ to market, we are pleased to see progress on other products in the portfolio in countries where CT:VQ is yet to receive regulatory clearance."
Fouras added:
4DMedical is committed to Australian healthcare and is excited to support the National Lung Cancer Screening Program. This is a key piece of Australian healthcare infrastructure and we believe our suite of products can play a big role.
I am excited to have Royal Melbourne Hospital as the first Australian public hospital and Academic Medical Centre to roll out the 4DMedical suite, further extending the reach of our technology into frontline clinical practice.
Lastly, in Brazil, our partnership with a global pharmaceutical offers further evidence of the growth of our reputation and a real opportunity to expand our reach to millions in South America.
